Turnover: ()
Country: France
Paris-listed French biotech startup
News
Abivax: French biotech nugget on track to raise 250 million euros on Wall Street 21/10/2023
- Abivax is a French biotechnology company specializing in chronic inflammatory diseases.
- Abivax plans to raise 250 million euros through a dual listing on the US stock exchange and a private placement in Europe, in addition to the 280 million euros raised since the beginning of the year.
- The potential market for Obefazimod, a drug candidate for treating ulcerative colitis, is estimated at between $5 and $10 billion.
- 70% of sales in inflammatory diseases are generated in the United States.